SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the implications of bacterial illnesses, introduced at this time the pricing of an underwritten public providing of widespread inventory and pre-funded warrants. Vaxcyte is promoting 15,000,000 shares of widespread inventory and pre-funded warrants to buy 3,750,000 shares of widespread inventory within the providing. The shares of widespread inventory are being offered at a public providing value of $32.00 per share, and the pre-funded warrants are being offered at a public providing value of $31.999 per underlying share. The mixture gross proceeds to Vaxcyte from this providing are anticipated to be roughly $600.0 million, earlier than deducting underwriting reductions and commissions and different providing bills, and excluding the train of any pre-funded warrants. All shares of widespread inventory and pre-funded warrants to be offered within the providing will likely be provided by Vaxcyte. Vaxcyte has granted the underwriters a 30-day choice to buy as much as an extra 2,812,500 shares of its widespread inventory on the public providing value per share, much less underwriting reductions and commissions.
The providing is predicted to shut on October 28, 2022, topic to the satisfaction of customary closing circumstances.
BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities are performing as joint book-running managers for the providing. Cantor is performing as lead supervisor for the providing. Needham & Company and BTIG are performing as co-managers for the providing.
A shelf registration assertion referring to the provided securities was filed with the Securities and Exchange Commission (SEC), and was routinely efficient upon submitting on July 2, 2021. A preliminary prospectus complement and accompanying prospectus referring to the providing has been filed, and a closing prospectus complement and accompanying prospectus referring to the providing will likely be filed with the SEC and will likely be obtainable on the SEC’s web site, positioned at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus referring to this providing could also be obtained, when obtainable, from BofA Securities NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, third Floor, Charlotte, North Carolina 28255 or by e mail at [email protected]; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, New York 10022, by phone at 1-877-821-7388, or by e mail at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, fortieth Floor, Boston, MA 02109, by e mail at [email protected] or by cellphone at (800) 808-7525, ext. 6105; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, thirty fifth Floor, New York, New York 10055, by phone at 1-888-474-0200 or by e mail at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, eighth Floor, New York, New York 10017, by phone at (212) 518-9544, or by e mail at [email protected].
This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase these securities nor shall there be any sale of these securities in any state or jurisdiction by which such provide, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About Vaxcyte
Vaxcyte is a vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the implications of bacterial illnesses. The Company is growing broad-spectrum conjugate and novel protein vaccines to forestall or deal with bacterial infectious illnesses. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal illness. Vaxcyte is re-engineering the way in which extremely complicated vaccines are made by trendy artificial methods, together with superior chemistry and the XpressCFTM cell-free protein synthesis platform, completely licensed from Sutro Biopharma, Inc. Unlike typical cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is meant to speed up its capability to effectively create and ship high-fidelity vaccines with enhanced immunological advantages. Vaxcyte’s pipeline additionally consists of VAX-XP, a PCV with protection of 31 strains; VAX-A1, a prophylactic vaccine candidate designed to forestall Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to sluggish or cease the development of periodontal illness. Vaxcyte is pushed to eradicate or deal with invasive bacterial infections, which have severe and expensive well being penalties when left unchecked.
Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
[email protected]
Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
[email protected]
